Demographic and disease characteristics at the start of methotrexate use (n = 204). Data are mean (SD) unless otherwise indicated.
| Variables | Values |
|---|---|
| Sex, male, n (%) | 110 (53.9) |
| Age, yrs | 47.1 (13.5) |
| Duration of psoriasis, yrs | 17.0 (13.2) |
| Duration of PsA, yrs | 6.2 (8.0) |
| Smoking status, n (%) | |
| None | 128 (63.7) |
| Current | 28 (13.9) |
| Past | 45 (22.3) |
| PASI | 5.5 (8.0) |
| BSA, % affected | 9.1 (14.2) |
| ESR, mm/h | 19.1 (18.5) |
| CRP, mg/l | 14.6 (22.3) |
| Tender joint count | 10.2 (10.7) |
| Swollen joint count | 6.0 (7.4) |
| Body mass index, kg/m2 | 30.5 (6.9) |
| Dactylitis, n (%) | 53 (26.1) |
| Enthesitis, n (%) | 48 (23.5) |
| NSAID, n (%) | 106 (52.0) |
| Leflunomide, n (%) | 9 (4.4) |
| PGA (out of 10) | 2.6 (0.9) |
| PtGA* | 2.5 (0.9) |
| Patient pain score* | 5.3 (2.4) |
| HAQ | 0.8 (0.7) |
| CASPAR criteria, n (%) | 204 (100) |
↵* These were scored out of 10 and transformed into their centile equivalent for the purposes of MDA calculation. MDA: minimal disease activity; PsA: psoriatic arthritis; PASI: Psoriasis Area Severity Index; BSA: body surface area; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; NSAID: nonsteroidal antiinflammatory drugs; HAQ: Health Assessment Questionnaire; CASPAR: Classification of Psoriatic Arthritis criteria; PGA: physician’s global assessment; PtGA: patient’s global assessment.